Concord Biotech
₹1,339-14.30 (-1.06%)as of 2026-10-16
- Market Cap
- ₹14,035Cr.
- P/E Ratio
- 49.4
- P/B Ratio
- 6.94
- EPS (TTM)
- ₹27.11
- Day Range
- ₹1,332 – ₹1,366.8
- Div Yield
- 0.55%
- ROCE
- 17.4%
- ROE
- 12.6%
52W Low: ₹98752W High: ₹1,615
Themes:💊 Pharma & CDMO
Appears in 1 screen
Descriptive screens built from published data — not investment advice.
At a glance
- Sales have grown 7.0% a year over three years.
- Debt is 0.00× its shareholders’ equity.
From reported financials and exchange prices. Descriptive only, not advice.
Concord_Biotech — Price
Interval
Style
Failed: 503
Evenstocks Score
Middle third
Overall
Valuation
Quality
Fundamental
Growth
Investment Checklist
Quick assessment based on key parametersPerformance
N/ATrailing return unavailableValuation
P/E 49.4P/E: 49.4 | P/B: 6.94Growth
ModestSales CAGR — 3Y: 7% · 1Y: -6%Profitability
ModerateROCE: 17.4% | ROE: 12.6%Key Metrics
Valuation
PEG Ratio 49.40
Price / Sales 12.62x
Price / FCF 83.0x
Book Value ₹193
Margins & returns
Operating Margin 36%
Net Margin 25.4%
Return on Assets 12.6%